Zahra Mahmoudjafari, PharmD, BCOP, DPLA, opens a discussion surrounding chronic lymphocytic leukemia (CLL).
The Use of Combination Therapies in the Frontline Setting for CLL
Dr Mahmoudjafari highlights the changing treatment landscape for patients with CLL.
CAPTIVATE FD and GLOW studies results and takeaways are discussed by Dr Mahmoudjafari.
Dr Mahmoudjafari explores the role of BTK inhibitors in the treatment of CLL.
In her closing thoughts, Dr Mahmoudjafari provides an overview of cardiovascular implications associated with CLL as well as the impact of pharmacists in CLL treatment management.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nerandomilast Receives FDA Approval for Idiopathic Pulmonary Fibrosis
2
Study Shows Infliximab Biosimilar is Safe in Patients Undergoing RA Treatment
3
Dexamethasone-Sparing Regimen Offers Safer Option for Frail Patients With MM
4
Pneumococcal Polysaccharide Vaccination Does Not Reduce Rates of Cardiovascular Events
5
